🇺🇸 FDA
Patent

US 12173062

Modified TNF-α antibodies and uses thereof

granted A61KA61K38/2013A61K47/6813

Quick answer

US patent 12173062 (Modified TNF-α antibodies and uses thereof) held by Bright Peak Therapeutics AG expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bright Peak Therapeutics AG
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K38/2013, A61K47/6813, A61K47/6845, A61P